Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8080567 | EPreceptor agonists A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the g... | 12/20/2011 |
| 7803841 | EPreceptor agonists The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor. ... | 09/28/2010 |
| 7662839 | EP2 receptor agonists A compound of formula (I): or a salt, or chemically protected form thereof, wherein: R5 is an optionally substituted phenyl; A is | 02/16/2010 |
| 7189689 | Apolipoprotein A-L agonists and their use to treat dyslipidemic disorders The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia. ... | 03/13/2007 |
| 7045653 | Pharmaceuticals The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R1 is C1–C6alkyl, C1–C6alkoxyC1–C3alkyl or... | 05/16/2006 |
| 6916805 | Quinoxalinones as serine protease inhibitors This invention discloses quinoxalinones which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable co... | 07/12/2005 |
| 6855726 | Quinolones as serine protease inhibitors The invention discloses quinolinones which display inhibitory effects on serine proteases such as factor Xa, thrombin and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compos... | 02/15/2005 |
| 6773896 | Method for direct measurement of coagulation factor VIIa activity in plasma The present invention generally provides a method of measuring the biological activity of Coagulation Factor VIIa (Factor VIIa). Specifically, the present invention provides a method for directly measuring the activity of Factor VIIa in a plasma sample. More specifi... | 08/10/2004 |
| 6750194 | Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors Screening methods for identifying compounds that regulate skeletal muscle atrophy or hypertrophy, regulate the activity or expression of the vasoactive intestinal peptide receptors (VPAC) or regulate expression of vasoactive intestinal peptide (VIP) or VIP analogs a... | 06/15/2004 |
| 6670140 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2 R) and regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening metho... | 12/30/2003 |
